## IN THIS ISSUE
Highlighted research articles ........................................ viii

## NEWS IN BRIEF
Important news stories affecting the community ...................... 368

## NEWS IN DEPTH
Q&A: Phillip Sharp on Biomedical Convergence ................. 370
Drugs, Diagnostic Tests Approved Quickly ......................... 371
Speed Traps for Trials .................................................. 372

## RESEARCH WATCH
Selected highlights of recent articles of exceptional significance from the cancer literature ................... 374

## VIEWS
In The Spotlight

**The Prospects of HPV Vaccination in Cervical Cancer Prevention: Results of a New Independent Trial** .... 377
F.X. Bosch, S. de Sanjose, and X. Castellsague
Commentary on Herrero et al., p. 408

**Nuclear Receptor LXR as a Novel Therapeutic Antitumoral Target in Glioblastoma** ............... 381
A. Moschetta
Commentary on Guo et al., p. 442

### Prospective

**Forty Years of Translational Cancer Research** ............... 383
*WN. Hait*

### REVIEW

**The Emergence of lncRNAs in Cancer Biology** .......... 391
*J.R. Prensner and A.M. Chinnaiyan*

### RESEARCH ARTICLES

**Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica** ........... 408

**Précis:** Cervical cancer prevention efforts in developing countries should focus on vaccination of young women prior to sexual activity.

**Variants in Inflammation Genes Are Implicated in Risk of Lung Cancer in Never Smokers Exposed to Second-hand Smoke** ....... 420

**Précis:** A variant of the TGF-β receptor ACVR1B increases risk of NSCLC in never smokers exposed to environmental tobacco smoke.
TGF-β Receptor II Loss
Promotes Mammary Carcinoma
Progression by Th17-Dependent
Mechanisms ........................................ 430
S.V. Novitskiy, M.W. Pickup, A.E. Gorska,
P. Owens, A. Chytil, M. Aakre, H. Wu,
Y. Shyr, and H.L. Moses
Précis: IL-17 contributes to immune evasion
in TGF-β receptor II-deficient tumors and
represents a novel therapeutic target.

An LXR Agonist Promotes Glioblastoma
Cell Death through Inhibition of
an EGFR/AKT/SREBP-1/LDLR-
Dependent Pathway ............................. 442
D. Guo, F. Reinitz, M. Youssef, C. Hong, D. Nathanson,
D. Akhavan, D. Kuga, A.N. Amzajerdi, H. Soto,
S. Zhu, I. Babic, K. Tanaka, J. Dang, A. Iwanami,
B. Gini, J. DeJesus, D.D. Lisiero, T.T. Huang,
R.M. Prins, P.Y. Wen, H.I. Robins, M.D. Prados,
L.M. DeAngelis, I.K. Mellinghoff, M.P. Mehta,
C.D. James, A. Chakravarti, T.F. Cloughesy,
P. Tontonoz, and P.S. Mischel
Précis: Inhibition of cholesterol metabolism is
a novel therapeutic strategy for EGFR-mutant
glioblastomas.

ON THE COVER
Herrero and colleagues demonstrate that Cervarix, a bivalent ASO4-
adjuvanted HPV16/18 vaccine, is over 90% effective in preventing
persistent infection in HPV-negative women among a large Costa
Rican population with a high incidence of cervical cancer, but its ef-
cicacy diminishes with age and sexual experience. One of the first
public HPV vaccine trials, this study underscores the importance of
early HPV vaccination in cervical cancer prevention, particularly in developing
countries. For details, please see the article by Herrero and colleagues on
page 408.